Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Research and Innovation Action · Running

I3LUNG Integrative science, Intelligent data platform for Individualized LUNG cancer care with Immunotherapy

Coordinator
Fondazione Irccs Istituto Nazionale Dei Tumori, Italy
Runs
1 June 2022 to 31 May 2027
Status
Running
EU funding
€10.0m
Total cost
€10.0m
Partners
16 organisations in 10 countries
Type
Research and Innovation Action
Grant agreement
101057695

What the project is doing

In the project's own words, from its summary on CORDIS.

Immunotherapy (IO) is the new standard of care for many patients with advanced Non-Small Cell Lung Cancer (aNSCLC), yet only around 30-50% of treated patients benefit from IO in the long term. Programmed Death-Ligand 1 (PD-L1) remains the only biomarker used to predict patient outcome to IO, though its efficacy is limited. Other potential biomarkers have been identified, yet not validated in prospective randomized clinical trials, providing only partial evidence.

Due to the dynamic complexity of the immune system-tumour microenvironment, its interaction with the host and patient behaviour, it?s unlikely for a single biomarker to accurately predict patient outcome. Artificial Intelligence (AI) and machine learning (ML) frameworks, that synthetize and correlate information from multiple sources, are essential to develop powerful decision-making tools able to deal with this highly complex context and provide individualized predictions to improve patient outcomes reducing the economic burden of health care systems in NSCLC.

The aim of the I3LUNG project is to develop such AI-based tools to assist in improving survival and quality of life, preventing undue toxicity, and reducing treatment costs. I3LUNG adopts a two-pronged approach: setting up a transnational platform of available data from 2000 patients in order to validate the AI models, and generating a multi-omics prospective data collection in 200 NSCLC patients integrating diverse -omic information then validate its usefulness in leading IO therapeutic decisions.

A psychological study will help in defining the impact of AI-guided decisions on patients, eliciting their preference, and physicians comparing AI with Human Intuition. The final goal is the construction of a novel integrated AI-assisted Data Storage and Elaboration Platform backed up by Trustworthy Explainable AI methodology, ensuring its accessibility and ease of use by healthcare providers and patients alike.

Topics

Who is involved

OrganisationCityCountryRole
Fondazione Irccs Istituto Nazionale Dei TumoriMilanItalyCoordinator
Katholieke Universiteit LeuvenLeuvenBelgiumParticipant
Lung Cancer Europe LuceBernSwitzerlandAssociatedpartner
Lungenclinic Grosshansdorf GmbHGrosshansdorfGermanyParticipant
Universitaetsklinikum Hamburg-EppendorfHamburgGermanyParticipant
Aalborg UniversitetAalborgDenmarkParticipant
Perseys Anonymos Etaireia Ekmetallefsis Leitoyrgeias Foreon Ygeionomikis MerimnasAthinaGreeceParticipant
Fundacio Privada Institut D'investigacio Oncologica De Vall-Hebron (vhio)BarcelonaSpainParticipant
Medica Scientia Innovation Research SLValenciaSpainParticipant
Shaare Zedek Medical CenterJerusalemIsraelParticipant
Istituto Di Ricerche Farmacologiche Mario NegriMilanoItalyParticipant
Istituto Europeo Di Oncologia SRLMilanoItalyParticipant
Ml Cube S.r.l.MilanoItalyParticipant
Politecnico Di MilanoMilanoItalyParticipant
Ihe, Institutet for Halso- Och Sjukvardsekonomi AktiebolagLundSwedenParticipant
The University of ChicagoChicago IllinoisUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI